Veracyte, Inc. (VCYT) shareholders
Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 11,930,018 | 15.20% | 13G (passive) amendment | Jul 31, 2025 |
| Artisan Investments GP LLC Joint filing with Artisan Partners Asset Management Inc. (9.40%), Artisan Partners Holdings LP (9.40%) and 1 more | 7,370,467 | 9.40% | 13G (passive) amendment | Sep 30, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (8.60%) | 6,735,697 | 8.60% | 13G (passive) amendment | Sep 30, 2025 |
| Artisan Partners Limited Partnership Joint filing with Artisan Partners Asset Management Inc. (8.10%), Artisan Partners Holdings LP (8.10%) and 1 more | 6,321,775 | 8.10% | 13G (passive) amendment | Jun 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (7.70%) | 6,172,996 | 7.70% | 13G (passive) amendment | Sep 30, 2026 |
| Artisan Partners Asset Management Inc. Joint filing with Artisan Partners Holdings LP (6.90%), Artisan Investments GP LLC (6.90%) and 1 more | 5,496,370 | 6.90% | 13G (passive) amendment | Mar 31, 2026 |
| State Street Corporation | 5,043,590 | 6.30% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 4,512,852 | 5.67% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 4,132,224 | 5.20% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VCYT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,486,437 | 16.78% | $792.06M | +313,819 | 0.01% |
| FMR LLC | 7,702,746 | 9.58% | $452.38M | −61,103 | 0.02% |
| Artisan Partners Limited Partnership | 5,538,404 | 6.89% | $325.27M | +42,034 | 0.52% |
| Vanguard Portfolio Management LLC | 4,716,191 | 5.87% | $276.98M | +271,461 | 0.01% |
| State Street Corp | 4,698,128 | 5.84% | $275.95M | −345,462 | 0.01% |
| Vanguard Capital Management LLC | 3,593,922 | 4.47% | $211.07M | +61,690 | 0.00% |
| Dimensional Fund Advisors LP | 2,826,524 | 3.52% | $166.01M | −54,566 | 0.03% |
| First Trust Advisors LP | 2,507,902 | 3.12% | $147.29M | +390,856 | 0.09% |
| ARK Investment Management LLC | 2,295,951 | 2.86% | $134.84M | −757,867 | 0.88% |
| Wellington Management Group Llp | 2,274,160 | 2.83% | $133.56M | −284,125 | 0.02% |
| Geode Capital Management, LLC | 2,104,000 | 2.62% | $123.59M | +146,904 | 0.01% |
| Goldman Sachs Group Inc | 1,642,911 | 2.04% | $96.49M | +366,651 | 0.01% |
| Fuller & Thaler Asset Management, Inc. | 1,509,749 | 1.88% | $88.67M | +95,387 | 0.24% |
| William Blair Investment Management, LLC | 1,431,596 | 1.78% | $84.08M | +441,909 | 0.25% |
| GW&K Investment Management, LLC | 1,416,543 | 1.76% | $83.19M | −20,779 | 0.65% |
| Morgan Stanley | 1,191,790 | 1.48% | $69.99M | +393,988 | 0.00% |
| Bank Of America Corp /De/ | 1,102,279 | 1.37% | $64.74M | −346,618 | 0.00% |
| Driehaus Capital Management LLC | 1,045,826 | 1.30% | $61.42M | New | 0.36% |
| Northern Trust Corp | 996,154 | 1.24% | $58.50M | +66,654 | 0.01% |
| Charles Schwab Investment Management Inc | 939,983 | 1.17% | $55.21M | +16,410 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 370 | 89M | 100.0% | 80 / 128 | 122 / 41 | 9M | 8M |
| Q1 2026 | 334 | 88M | 100.0% | 48 / 142 | 102 / 37 | 18M | 8M |
| Q4 2025 | 329 | 88M | 100.0% | 65 / 108 | 115 / 28 | 8M | 10M |
| Q3 2025 | 298 | 90M | 100.0% | 70 / 95 | 90 / 46 | 17M | 12M |
| Q2 2025 | 278 | 85M | 100.0% | 36 / 102 | 103 / 43 | 10M | 9M |
| Q1 2025 | 287 | 85M | 100.0% | 27 / 112 | 107 / 56 | 12M | 8M |
| Q4 2024 | 318 | 82M | 100.0% | 54 / 105 | 121 / 25 | 11M | 11M |
| Q3 2024 | 293 | 82M | 100.0% | 77 / 87 | 91 / 22 | 19M | 11M |
| Q2 2024 | 240 | 83M | 100.0% | 26 / 90 | 85 / 29 | 7M | 7M |
| Q1 2024 | 246 | 83M | 100.0% | 35 / 118 | 66 / 37 | 9M | 4M |
| Q4 2023 | 250 | 78M | 97.0% | 35 / 80 | 105 / 20 | 5M | 4M |
| Q3 2023 | 236 | 77M | 95.3% | 28 / 97 | 79 / 20 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
345 funds held VCYT in Q2 2026, 54% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VCYT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4,807,245 | 5.98% | $282.33M | 0.25% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,532,110 | 3.15% | $148.71M | 0.01% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 2,441,185 | 3.04% | $143.37M | 5.10% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,079,919 | 2.59% | $122.15M | 0.15% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,830,642 | 2.28% | $107.51M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,496,464 | 1.86% | $87.89M | 0.82% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,280,000 | 1.59% | $59.32M | 1.03% | May 31, 2026 |
| Artisan Mid Cap Fund | 1,236,133 | 1.54% | $72.60M | 2.27% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,053,887 | 1.31% | $61.89M | 0.13% | Jun 30, 2026 |
| ARK Innovation ETF | 1,026,015 | 1.28% | $47.53M | 0.85% | Jul 31, 2026 |
| Select Medical Technology and Devices Portfolio | 1,000,000 | 1.24% | $46.34M | 1.56% | May 31, 2026 |
| Vanguard Explorer Fund | 983,816 | 1.22% | $45.57M | 0.21% | Jul 31, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 977,500 | 1.22% | $57.41M | 0.93% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 956,773 | 1.19% | $56.19M | 0.50% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 915,041 | 1.14% | $53.74M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marc Stapley | Chief Executive Officer, Director | 432,073 | 0.54% | Sep 4, 2026 |
| Jonathan Wygant | VP, Chief Accounting Officer | 41,920 | 0.05% | Oct 29, 2026 |
| John Leite | Global Chief Commercial Off | 124,329 | 0.15% | Sep 22, 2026 |
| Phillip G. Febbo | Chief Scientific & Med Officer | 133,048 | 0.17% | Sep 4, 2026 |
| Rebecca Chambers | Chief Financial Officer | 167,200 | 0.21% | Sep 4, 2026 |
| Annie McGuire | EVP, General Counsel | 132,260 | 0.16% | Sep 4, 2026 |
| Kevin Richard Haas | Chief Dev and Tech Officer | 44,221 | 0.06% | Apr 14, 2026 |
| Jens Holstein | Director | 27,471 | 0.03% | Oct 28, 2026 |
| Karin Eastham | Director | 11,488 | 0.01% | Oct 28, 2026 |
| Muna Bhanji | Director | 40,854 | 0.05% | Oct 20, 2026 |
| Robert S. Epstein | Director | 57,718 | 0.07% | Jun 15, 2026 |
| Evan/ Fa Jones | Director | 34,634 | 0.04% | Jun 15, 2026 |
| David Brent Shafer | Director | 31,100 | 0.04% | Jun 15, 2026 |
| Eliav Barr | Director | 56,461 | 0.07% | Jun 15, 2026 |
| Thomas F. Miller | Director | 31,100 | 0.04% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan Wygant VP, Chief Accounting Officer | Oct 28, 2026 | Tax withholding | −1,306 | $50.31 | $65.70K | 41,920 |
| Jens Holstein Director | Oct 27, 2026 | Sale(10b5-1 plan) | −7,500 | $50.00 | $375.00K | 27,471 |
| Jens Holstein Director | Oct 27, 2026 | Option exercise | +7,500 | $35.30 | $264.75K | 34,971 |
| Karin Eastham Director | Oct 27, 2026 | Sale(10b5-1 plan) | −14,850 | $50.00 | $742.57K | 10,247 |
| Karin Eastham Director | Oct 27, 2026 | Option exercise | +10,000 | $27.01 | $270.10K | 25,097 |
| Muna Bhanji Director | Oct 19, 2026 | Sale(10b5-1 plan) | −1,864 | $43.70 | $81.46K | 40,854 |
| Jens Holstein Director | Sep 24, 2026 | Sale(10b5-1 plan) | −7,500 | $47.00 | $352.50K | 27,471 |
| Jens Holstein Director | Sep 24, 2026 | Option exercise | +7,500 | $35.30 | $264.75K | 34,971 |
| John Leite Global Chief Commercial Off | Sep 21, 2026 | Sale(10b5-1 plan) | −4,015 | $40.00 | $160.60K | 124,329 |
| Jens Holstein Director | Sep 14, 2026 | Sale(10b5-1 plan) | −5,000 | $40.95 | $204.75K | 27,471 |
| Phillip G. Febbo Chief Scientific & Med Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −2,705 | $43.66 | $118.10K | 133,048 |
| Phillip G. Febbo Chief Scientific & Med Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −10,405 | $42.89 | $446.27K | 135,753 |
| Annie McGuire EVP, General Counsel | Sep 4, 2026 | Sale(10b5-1 plan) | −2,154 | $42.79 | $92.17K | 132,260 |
| Annie McGuire EVP, General Counsel | Sep 4, 2026 | Sale(10b5-1 plan) | −1,100 | $43.67 | $48.04K | 131,160 |
| Rebecca Chambers Chief Financial Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −2,477 | $42.81 | $106.04K | 167,200 |
| Rebecca Chambers Chief Financial Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −1,175 | $43.71 | $51.36K | 166,025 |
| Phillip G. Febbo Chief Scientific & Med Officer | Sep 2, 2026 | Tax withholding | −3,639 | $44.88 | $163.32K | 146,158 |
| John Leite Global Chief Commercial Off | Sep 2, 2026 | Tax withholding | −3,961 | $44.88 | $177.77K | 128,344 |
| Annie McGuire EVP, General Counsel | Sep 2, 2026 | Tax withholding | −3,215 | $44.88 | $144.29K | 134,414 |
| Rebecca Chambers Chief Financial Officer | Sep 2, 2026 | Tax withholding | −3,603 | $44.88 | $161.70K | 169,677 |
| Marc Stapley Chief Executive Officer, Director | Sep 2, 2026 | Tax withholding | −8,782 | $44.88 | $394.14K | 432,073 |
| Jonathan Wygant VP, Chief Accounting Officer | Sep 2, 2026 | Tax withholding | −1,361 | $44.88 | $61.08K | 43,226 |
| Muna Bhanji Director | Sep 1, 2026 | Sale(10b5-1 plan) | −1,864 | $42.97 | $80.10K | 42,718 |
| Karin Eastham Director | Jun 18, 2026 | Sale(10b5-1 plan) | −529 | $53.55 | $28.33K | 15,097 |
| Karin Eastham Director | Jun 18, 2026 | Sale(10b5-1 plan) | −3,200 | $52.78 | $168.90K | 15,626 |
| Jens Holstein Director | Jun 11, 2026 | Award | +5,272 | – | – | 32,471 |
| Karin Eastham Director | Jun 11, 2026 | Award | +5,272 | – | – | 18,826 |
| Evan/ Fa Jones Director | Jun 11, 2026 | Award | +5,272 | – | – | 34,634 |
| Thomas F. Miller Director | Jun 11, 2026 | Award | +5,272 | – | – | 31,100 |
| Robert S. Epstein Director | Jun 11, 2026 | Award | +5,272 | – | – | 57,718 |
| Eliav Barr Director | Jun 11, 2026 | Award | +5,272 | – | – | 56,461 |
| Muna Bhanji Director | Jun 11, 2026 | Award | +5,272 | – | – | 44,582 |
| David Brent Shafer Director | Jun 11, 2026 | Award | +5,272 | – | – | 31,100 |
| John Leite Global Chief Commercial Off | Jun 4, 2026 | Sale(10b5-1 plan) | −13,975 | $50.07 | $699.73K | 132,305 |
| Rebecca Chambers Chief Financial Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −1,961 | $50.09 | $98.23K | 173,280 |
| Rebecca Chambers Chief Financial Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −1,600 | $49.28 | $78.85K | 175,241 |
| Marc Stapley Chief Executive Officer, Director | Jun 4, 2026 | Sale(10b5-1 plan) | −138,051 | $50.12 | $6.92M | 440,494 |
| Marc Stapley Chief Executive Officer, Director | Jun 4, 2026 | Option exercise | +138,051 | $36.60 | $5.05M | 578,545 |
| Annie McGuire EVP, General Counsel | Jun 4, 2026 | Sale(10b5-1 plan) | −1,400 | $49.31 | $69.03K | 139,016 |
| Annie McGuire EVP, General Counsel | Jun 4, 2026 | Sale(10b5-1 plan) | −1,776 | $50.12 | $89.01K | 137,240 |
| John Leite Global Chief Commercial Off | Jun 2, 2026 | Tax withholding | −4,059 | $47.80 | $194.02K | 146,280 |
| Rebecca Chambers Chief Financial Officer | Jun 2, 2026 | Tax withholding | −3,693 | $47.80 | $176.53K | 176,841 |
| Phillip G. Febbo Chief Scientific & Med Officer | Jun 2, 2026 | Tax withholding | −3,730 | $47.80 | $178.29K | 149,797 |
| Jonathan Wygant VP, Chief Accounting Officer | Jun 2, 2026 | Tax withholding | −1,361 | $47.80 | $65.06K | 44,073 |
| Marc Stapley Chief Executive Officer, Director | Jun 2, 2026 | Tax withholding | −9,012 | $47.80 | $430.77K | 440,494 |
| Annie McGuire EVP, General Counsel | Jun 2, 2026 | Tax withholding | −3,292 | $47.80 | $157.36K | 140,416 |
| Jonathan Wygant VP, Chief Accounting Officer | May 22, 2026 | Sale | −24,000 | $45.40 | $1.09M | 45,434 |
| Jonathan Wygant VP, Chief Accounting Officer | May 22, 2026 | Option exercise | +24,000 | $24.80 | $595.20K | 69,434 |
| Robert S. Epstein Director | May 20, 2026 | Sale(10b5-1 plan) | −10,000 | $44.01 | $440.10K | 52,446 |
| Annie McGuire SVP, General Counsel | May 6, 2026 | Sale(10b5-1 plan) | −5,102 | $40.00 | $204.08K | 143,708 |
| Annie McGuire SVP, General Counsel | May 6, 2026 | Sale(10b5-1 plan) | −5,102 | $38.05 | $194.13K | 148,810 |
| Kevin Richard Haas Chief Dev and Tech Officer | Apr 10, 2026 | Award | +44,221 | – | – | 44,221 |
| Rebecca Chambers Chief Financial Officer | Mar 6, 2026 | Award | +13,157 | – | – | 180,534 |
| Rebecca Chambers Chief Financial Officer | Mar 6, 2026 | Award | +36,181 | – | – | 167,377 |
| Annie McGuire SVP, General Counsel | Mar 6, 2026 | Award | +26,314 | – | – | 153,912 |
| Annie McGuire SVP, General Counsel | Mar 6, 2026 | Award | +32,892 | – | – | 127,598 |
| Marc Stapley Chief Executive Officer, Director | Mar 6, 2026 | Award | +92,099 | – | – | 449,653 |
| Jonathan Wygant VP, Chief Accounting Officer | Mar 6, 2026 | Award | +10,525 | – | – | 45,434 |
| Phillip G. Febbo Chief Scientific & Med Officer | Mar 6, 2026 | Award | +29,603 | – | – | 146,949 |
| Phillip G. Febbo Chief Scientific & Med Officer | Mar 6, 2026 | Award | +6,578 | – | – | 153,527 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Veracyte's stock actually held short. Settlement fails (shares not delivered on time) peaked at 23,770 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Karin Eastham Director | Oct 27, 2026 | 14,850 | $715.77K | Oct 27, 2026 | Exercise of Stock Options |
| Jens Holstein Director | Oct 27, 2026 | 7,500 | $375.00K | Oct 27, 2026 | Stock Option Exercise |
| Jens Holstein Director | Sep 24, 2026 | 7,500 | $352.50K | Sep 24, 2026 | Stock Option Exercise |
| John Leite Officer | Sep 21, 2026 | 4,015 | $159.78K | Sep 21, 2026 | Restricted Stock Units |
| Jens Holstein Director | Sep 14, 2026 | 5,000 | $204.75K | Sep 14, 2026 | Restricted Stock |
| Ann McGuire Officer | Sep 4, 2026 | 3,254 | $145.36K | Sep 4, 2026 | Restricted Stock Units |
| Phillip G. Febbo Officer | Sep 4, 2026 | 13,110 | $585.62K | Sep 4, 2026 | Restricted Stock Units |
| Rebecca Chambers Officer | Sep 4, 2026 | 3,652 | $163.13K | Sep 4, 2026 | Restricted Stock Units |
| Muna Bhanji Director | Sep 1, 2026 | 3,728 | $161.01K | Sep 1, 2026 | Restricted Stock Units |
| Karin Eastham Director | Jun 18, 2026 | 3,729 | $191.26K | Jun 18, 2026 | Restricted Stock Units |
| Ann McGuire Officer | Jun 4, 2026 | 3,176 | $154.64K | Jun 4, 2026 | Restricted Stock Units |
| John Leite Officer | Jun 4, 2026 | 13,975 | $680.44K | Jun 4, 2026 | Restricted Stock Units |
| Marc Stapley Director, Officer | Jun 4, 2026 | 138,051 | $6.72M | Jun 4, 2026 | Exercise of Stock Options |
| Rebecca Chambers Officer | Jun 4, 2026 | 3,561 | $173.39K | Jun 4, 2026 | Restricted Stock Units |
| Robert S. Epstein Director | May 20, 2026 | 10,000 | $416.90K | May 20, 2026 | Previously Exercised Stock Options |
Congress trades
14 trades in Veracyte reported by 3 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Mar 3, 2026 | $1K–15K | Apr 7, 2026 |
| Gilbert Cisneros CA31 | Sold (part) | Nov 12, 2025 | $1K–15K | Dec 15, 2025 |
| Gilbert Cisneros CA31 | Bought | Jun 16, 2025 | $1K–15K | Jul 10, 2025 |
| Josh Gottheimer NJ05 · joint account | Bought | Oct 16, 2023 | $1K–15K | Nov 11, 2023 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Sep 15, 2023 | $1K–15K | Oct 15, 2023 |
| Daniel Goldman NY10 | Sold (part) | Apr 10, 2023 | $1K–15K | May 19, 2023 |
| Gilbert Cisneros CA31 | Sold (part) | Dec 23, 2020 | $1K–15K | Jan 11, 2021 |
| Gilbert Cisneros CA31 | Sold (part) | Dec 10, 2020 | $1K–15K | Jan 11, 2021 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Dec 8, 2020 | $1K–15K | Jan 7, 2021 |
| Gilbert Cisneros CA31 | Sold (part) | Oct 29, 2020 | $1K–15K | Nov 5, 2020 |
| Gilbert Cisneros CA31 | Bought | Jan 17, 2020 | $1K–15K | Feb 18, 2020 |
| Gilbert Cisneros CA31 | Bought | Dec 24, 2019 | $1K–15K | Jan 10, 2020 |
| Gilbert Cisneros CA31 | Bought | Dec 12, 2019 | $1K–15K | Jan 10, 2020 |
| Josh Gottheimer NJ05 · joint account | Bought | Dec 6, 2019 | $1K–15K | Jan 6, 2020 |
See a number that looks wrong?